

Soft Tissue Sarcoma Market Poised for Growth, Expected to Reach \$4.3 Billion by 2028

The Business Research Company's Soft Tissue Sarcoma Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 3, 2024 /EINPresswire.com/ -- The soft tissue sarcoma market size has grown strongly in recent years, from \$2.87 billion in 2023 to \$3.13 billion in 2024,

at a compound annual growth rate (CAGR) of 9.3%. The market is anticipated to continue its growth trajectory, reaching \$4.3 billion by 2028 at a CAGR of 8.2%. It will grow to \$4.3 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. This growth is driven by advancements in targeted therapies, increased focus on personalized medicine, and expansion of clinical trials for sarcoma treatments.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs
”

*The Business Research
Company*

Increasing Healthcare Expenditure Propels Market Growth

The increasing healthcare expenditure is expected to propel the growth of the soft tissue sarcoma market. Healthcare refers to the organized provision of medical services, treatments, preventive care, and management of health-related issues for individuals or communities.

Higher healthcare expenditures can result in increased funding for medical research, including cancer research. This can lead to advancements in understanding soft tissue sarcoma, discovering new treatment modalities, and improving overall patient outcomes. For instance, in the Economic Survey of 2022, an annual document of the Ministry of Finance, Government of India, India's public expenditure on healthcare stood at 2.1% of GDP in 2021–22. Moreover, according to a survey of global medical insurers conducted by Willis Towers Watson Public Limited Company, a British-American company providing insurance services, healthcare benefit costs increased from 8.2% in 2021 to 8.8% in 2022 and are expected to grow again in 2023 to a high global average of 10%. Therefore, the increased healthcare expenditure will drive the



The Business
Research Company

Soft Tissue Sarcoma Market Report 2024 – Market Size, Trends, And Forecast 2024-2033

growth of the soft tissue sarcoma market.

Explore comprehensive insights into the global soft tissue sarcoma market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=12211&type=smp

Major Players and Market Trends

Major companies operating in the soft tissue sarcoma market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co. Ltd., and Nanobiotix S.A.

Research Projects Drive Innovation

Major companies operating in the soft tissue sarcoma market are focusing on research projects such as the Leiomyosarcoma Project (LMS) to sustain their position in the market.

Leiomyosarcoma Project (LMS) refers to a project that aims to advance scientific discovery and understanding of leiomyosarcoma, which is a rare and aggressive form of cancer that arises in smooth muscle cells, typically found in the walls of organs like the uterus, stomach, or intestines. For instance, in September 2022, Count Me In, a US-based non-profit cancer research initiative, launched the Leiomyosarcoma Project (LMS), inviting individuals with the rare cancer leiomyosarcoma to actively participate in research. This initiative aims to accelerate scientific discovery and enhance understanding of leiomyosarcoma by partnering with patients. Count Me In already runs the Osteosarcoma Project (OS), another rare cancer research effort, following a similar patient-partnered model. In these projects, patients are encouraged to share their health data, contributing to a collaborative and data-driven approach to advance research and improve outcomes for individuals with these rare cancers.

Segments:

The soft tissue sarcoma market covered in this report is segmented –

- 1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments
- 2) By Route of Administration: Oral, Parenteral, Other Routes of Administration
- 3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Geographical Insights: North America Leading the Market

North America was the largest region in the soft tissue sarcoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access the complete report for an in-depth analysis of the global soft tissue sarcoma market:
<https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report>

[Soft Tissue Sarcoma Global Market Report 2024](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Soft Tissue Sarcoma Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on soft tissue sarcoma market size, soft tissue sarcoma market drivers and trends, soft tissue sarcoma market major players, competitors' revenues, market positioning, and market growth across geographies. The soft tissue sarcoma market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Gene Editing Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report>

Gene Therapy Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report>

Stem Cell Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724789612>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.